RBC Capital has increased its price target for Abbott Laboratories (ABT, Financial), raising it to $145 from the previous $140 while maintaining an Outperform rating on the stock. This adjustment comes as the company's first-quarter performance showcased robust underlying business trends, despite the challenging macroeconomic environment.
The firm highlights Abbott's impressive 8.3% year-over-year growth in underlying business and double-digit earnings per share (EPS) growth, which are significant given the company's substantial revenue base. RBC is particularly optimistic about Abbott's sustained high-single-digit revenue growth and continued double-digit EPS expansion, even as it navigates tariff pressures while holding its full-year guidance steady.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 23 analysts, the average target price for Abbott Laboratories (ABT, Financial) is $140.41 with a high estimate of $158.00 and a low estimate of $111.34. The average target implies an upside of 8.25% from the current price of $129.70. More detailed estimate data can be found on the Abbott Laboratories (ABT) Forecast page.
Based on the consensus recommendation from 28 brokerage firms, Abbott Laboratories's (ABT, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Abbott Laboratories (ABT, Financial) in one year is $118.41, suggesting a downside of 8.7% from the current price of $129.7. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Abbott Laboratories (ABT) Summary page.
